Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy

BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with (177)Lu-labeled PSMA ligands has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However, not all patients benefit from this therapy. Diffe...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Nucl Med Mol Imaging
Main Authors: Michalski, Kerstin, Ruf, Juri, Goetz, Christian, Seitz, Anna Katharina, Buck, Andreas K., Lapa, Constantin, Hartrampf, Philipp E.
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8113196/
https://ncbi.nlm.nih.gov/pubmed/33336265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05160-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items